Abbott Laboratories

Sensor Patch Market to Hit $28.9B by 2031 at 29.6% CAGR

Image
Sensor Patch Market to Hit $28.9B by 2031 at 29.6% CAGR

Sheridan – October 14, 2026 -- The global sensor patch market is valued at USD 7.9 billion in 2026 and is projected to reach USD 28.9 billion by 2031, a CAGR of 29.6%, according to a study by Wissen Research.

Chronic disease burden drives demand for remote monitoring

Sensor patches are adhesive, skin-worn devices that measure signals such as glucose, cardiac activity, and temperature and transmit the data wirelessly to a smartphone, cloud platform, or clinician. The World Health Organization links chronic disease to about 41 million deaths a year, roughly 71% of all deaths worldwide. The International Diabetes Federation estimates that about 589 million adults aged 20-79 had diabetes in 2024.

As care shifts to remote and home settings, continuous glucose monitoring (CGM) and ambulatory cardiac patches are becoming core tools for managing long-term conditions outside the clinic.

RPM Market to Nearly Double to $62.2B by 2031, Wissen Research Finds

Image
RPM Market to Nearly Double to $62.2B by 2031, Wissen Research Finds

Sheridan, Wyoming – September 21, 2026 -- The global remote patient monitoring (RPM) market is set to grow from $34.5 billion in 2026 to $62.2 billion by 2031, a 12.5% compound annual growth rate, according to a new study by Wissen Research.

Reimbursement codes and readmission penalties push hospitals toward RPM at scale

Dedicated CMS billing codes are giving U.S. providers a recurring revenue incentive to deploy RPM, while health systems use the technology to avoid costly 30-day readmission penalties tied to chronic disease relapse. Cardiovascular disease held the largest application share in 2025, reflecting the clinical and financial burden of heart failure, atrial fibrillation and hypertension.

Abbott Biosimilars Drive Cancer Treatment Access in Emerging Markets

Image

SHERIDAN, WYOMING - April 13, 2026 - Abbott's biosimilars medicines business is accelerating access to advanced biologic cancer therapies across emerging markets, where today only 0.1% of new biologic medicines are launched compared to 2%-3% penetration in developed markets. The disparity matters because emerging-market countries account for 57% of new cancer diagnoses globally and 65% of cancer deaths each year. Biosimilars - high-quality copies of approved biologic medicines with no meaningful difference in quality, safety, or efficacy - represent Abbott's core mechanism for closing that gap. With global cancer cases projected to climb from 20 million annually to more than 35 million by 2050, the business and public health stakes of biosimilar adoption are substantial.

Abbott's Piccolo Device and Similac Nutrition Support Premature Infant Through 76-Day NICU Stay

Image

SHERIDAN, WYOMING - April 13, 2026 - Abbott's Amplatzer Piccolo Occluder and Similac nutritional products played central roles in the care of Havana Caouette, a premature infant born at 30 weeks who spent 76 days in the neonatal intensive care unit (NICU) before discharge. The case illustrates how catheter-based cardiac closure devices and fortified infant nutrition formulas work in combination to address the compounding clinical challenges premature births typically generate. For neonatal care teams and hospital procurement officers, the case reinforces the operational value of having minimally invasive cardiac intervention tools available within the NICU setting.